Evaluation of Maximal Use of Ruxolitinib Cream in Adolescents and Adults With Hidradenitis Suppurativa

What this Trial Is About

Researchers are evaluating the maximal use of ruxolitinib cream in adolescents and adults with hidradenitis suppurativa, a chronic skin condition characterized by painful abscesses and nodules. This phase 1 trial aims to study the safety and pharmacokinetics of ruxolitinib cream applied topically in affected areas, focusing on participants with moderate to severe disease involving multiple body regions. Participants will apply ruxolitinib 1.5% cream as a thin layer twice daily to the affected skin areas. The study follows a single-group design without a placebo or comparison group, with treatment and observation lasting up to 24 weeks. During this period, participants avoid using other topical or systemic antibiotics for their condition. Throughout the study, participants will undergo regular assessments to monitor any treatment-emergent adverse events, including events leading to treatment interruption or discontinuation. Pharmacokinetic measures such as maximum concentration, time to maximum concentration, and area under the curve of the drug in the body will be collected. The study spans from screening through 24 weeks of treatment, with safety and drug behavior carefully tracked during this time.

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa